Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Declines By 50.0%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totaling 22,521 shares, a decline of 50.0% from the June 30th total of 45,019 shares. Based on an average daily trading volume, of 33,926 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.1% of the company’s shares are sold short.

China SXT Pharmaceuticals Trading Down 20.8%

NASDAQ SXTC opened at $0.06 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76. The firm has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $6.82. China SXT Pharmaceuticals has a one year low of $0.05 and a one year high of $1,046.98.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its earnings results on Wednesday, July 1st. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $0.26 million for the quarter.

Institutional Trading of China SXT Pharmaceuticals

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in shares of China SXT Pharmaceuticals in the third quarter valued at $78,000. Virtu Financial LLC increased its holdings in China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares during the period. Finally, XTX Topco Ltd acquired a new stake in China SXT Pharmaceuticals in the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, July 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, China SXT Pharmaceuticals presently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.